Myeliviz, a new drug to help diagnose multiple sclerosis in its earlier stages was recently approved by the FDA for human clinical trials.
The drug aims to provide new evidence to help diagnose MS and evaluate the scope of damage inflicted on the central nervous system.
Researchers from Cleveland-based Case Western Reserve University developed the drug, which will be tested in healthy volunteers at Cleveland Clinic Mellen Center for Multiple Sclerosis.
Administered through an IV before a PET scan, Myeliviz targets and binds to myelin, the casing surrounding nerves affected by MS.
The National Institutes of Health provided a $1.7 million grant to make the trial possible.